Literature DB >> 22244561

Prophylactic tricuspid annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery.

Umberto Benedetto1, Giovanni Melina, Emiliano Angeloni, Simone Refice, Antonino Roscitano, Cosimo Comito, Riccardo Sinatra.   

Abstract

OBJECTIVE: Progression of functional tricuspid regurgitation is not uncommon after mitral valve surgery and is associated with poor outcomes. We tested the hypothesis that concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (≥40 mm) prevents tricuspid regurgitation progression after mitral valve surgery.
METHODS: We enrolled 44 patients undergoing mitral valve surgery (both repair or replacement) showing less than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (≥40 mm) at preoperative echocardiography. They were randomized to receive (n = 22) or not receive (n = 22) concomitant tricuspid annuloplasty (Cosgrove-Edwards annuloplasty ring; Edwards Lifesciences, Irvine, Calif) at the time of mitral valve surgery. Clinical and echocardiographic follow-up was 100% completed at 12 months after surgery.
RESULTS: Preoperative clinical and echocardiographic characteristics were comparable in the 2 groups. Operative mortality was 4.4% (1 death in each group). At 12 months follow-up, tricuspid regurgitation was absent in 71% (n = 15) versus 19% (n = 4) of patients in the treatment and control groups, respectively (P = .001). Moderate to severe tricuspid regurgitation (≥+3) was present in 0% versus 28% (n = 6) of patients in the treatment and control groups, respectively (P = .02). Pulmonary artery systolic pressure significantly decreased from baseline in all cases (P < .001) and was comparable in the 2 groups (41 ± 8 mm Hg vs 40 ± 5 mm Hg; P = .4). Right ventricular reverse remodeling was marked in the treatment group (right ventricular long axis: 71 ± 7 mm vs 65 ± 8 mm; P = .01; short axis: 33 ± 4 mm vs 27 ± 5 mm; P = .001) but only minimal in the control group (right ventricular long axis: 72 ± 6 mm vs 70 ± 7 mm; P = .08; short axis: 34 ± 5 mm vs 33 ± 5 mm; P = .1). The 6-minute walk test improved from baseline in both groups (P < .001), but this improvement was greater in the treatment group (+115 ± 23 m from baseline vs +75 ± 35 m; P = .008).
CONCLUSIONS: Prophylactic tricuspid valve annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery was associated with a reduced rate of tricuspid regurgitation progression, improved right ventricular remodeling, and better functional outcomes. Copyright Â
© 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22244561     DOI: 10.1016/j.jtcvs.2011.12.006

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  28 in total

1.  New insight into tricuspid valve anatomy from 100 hearts to reappraise annuloplasty methodology.

Authors:  Yoshito Sakon; Takashi Murakami; Hiromichi Fujii; Yosuke Takahashi; Akimasa Morisaki; Kokoro Yamane; Masahiko Ohsawa; Ayumi Shintani; Toshiko Seki; Toshihiko Shibata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-02-25

2.  Three-dimensional echocardiography investigation of the mechanisms of tricuspid annular dilatation.

Authors:  Valentina Volpato; Victor Mor-Avi; Federico Veronesi; Karima Addetia; Megan Yamat; Lynn Weinert; Davide Genovese; Gloria Tamborini; Mauro Pepi; Roberto M Lang
Journal:  Int J Cardiovasc Imaging       Date:  2019-08-20       Impact factor: 2.357

3.  The impact of tricuspid annular geometry on outcome after percutaneous edge-to-edge repair for severe tricuspid regurgitation.

Authors:  Sylvia Otto; Marija Velichkov; Ali Hamadanchi; P Christian Schulze; Sven Moebius-Winkler
Journal:  Cardiol J       Date:  2021-05-04       Impact factor: 2.737

4.  Tricuspid valve annulus surgery during mitral valve surgery.

Authors:  Jeffrey Shuhaiber
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

5.  Long-term echocardiographic follow-up of untreated 2+ functional tricuspid regurgitation in patients undergoing mitral valve surgery.

Authors:  Kunio Kusajima; Tomoyuki Fujita; Hiroki Hata; Yusuke Shimahara; Sayaka Miura; Junjiro Kobayashi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-18

Review 6.  Surgical indication for functional tricuspid regurgitation at initial operation: judging from long term outcomes.

Authors:  Alberto Pozzoli; Elisabetta Lapenna; Luca Vicentini; Ottavio Alfieri; Michele De Bonis
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-21

7.  Functional tricuspid regurgitation: indications, techniques, and outcomes.

Authors:  Tessa M F Watt; Alexander A Brescia; Aaron M Williams; Steven F Bolling
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-01-09

Review 8.  How to Treat Tricuspid Valve Disease: What's New on the Horizon?

Authors:  Karina Brüstle; Christelle Calen; Shingo Kuwata; Fabian Nietlispach; Michel Zuber; Francesco Maisano; Maurizio Taramasso
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-03

9.  Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation.

Authors:  Alexander A Brescia; Sarah T Ward; Tessa M F Watt; Liza M Rosenbloom; Megan Baker; Shazli Khan; Emilie Ziese; Matthew A Romano; Steven F Bolling
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

10.  Tricuspid annulus: a three-dimensional deconstruction and reconstruction.

Authors:  Khurram Owais; Charles E Taylor; Luyang Jiang; Kamal R Khabbaz; Mario Montealegre-Gallegos; Robina Matyal; Joseph H Gorman; Robert C Gorman; Feroze Mahmood
Journal:  Ann Thorac Surg       Date:  2014-09-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.